Dr. Tracy Beth Høeg, the acting director of the FDA’s Center for Drug Evaluation and Research, is stepping down, marking another significant change within the agency. Her departure follows the resignation of FDA Commissioner Dr. Marty Makary, who left amid internal conflicts over the approval of flavored e-cigarettes. Høeg, who has been controversial due to her vaccine skepticism, had been in her role since December. Her appointment raised concerns among FDA officials, especially after she co-authored a memo linking children’s deaths to the COVID-19 vaccine without supporting data. Despite acknowledging the effectiveness of some vaccines, her leadership was seen as contentious. The FDA has recently experienced several high-level exits, including Dr. Vinay Prasad, who led the vaccine approval office. These changes highlight ongoing tensions and challenges within the agency as it navigates complex health decisions.
QUESTION: How might the recent leadership changes at the FDA impact public trust in the agency’s decisions on drug and vaccine approvals?
Controversial FDA official leaving drug center post in latest departure at agency
